ABBVIE INC.
NYSE: ABBV
▲
153.80
+0.64
+0.42%
1 Day
-
Open
153.08
-
Previous Close
153.16
-
Volume (Avg)
4.62M (6.56M)
-
Day's Range
151.46-153.86
-
52Wk Range
105.56-175.91
-
Market Cap.
271.78B
-
Dividend Rate (Yield)
5.64 (3.68%)
-
Beta
0.75
-
Shares Outstanding
1.77B
-
P/E Ratio (EPS)
21.97 (6.97)
Top Stories
-
3 Top Dividend Stocks for Generating Passive Income
The Motley Fool 6 days ago -
AbbVie Foundation spruces up Forest Grove MS as part of annual Week of Possibilities
Worcester Telegram -
Analyzing AbbVie's Short Interest
Benzinga -
AbbVie (ABBV) Files Qulipta sNDA for Chronic Migraine Prevention
Zacks.com -
Amgen's Beating the Market -- Here's Why It's a Buy Now
The Motley Fool 1 day ago -
Kristin Chenoweth Thought She Was 'Going to Have to Retire' Due to Her Chronic Migraine
People -
Pharma Stock Roundup: FDA OK's Expanded Use of ABBV, MRK, NVS Drugs, Other Updates
Zacks.com -
DEM BioPharma launches with $70m to take a bite out of cancer
The Boston Globe -
Is AbbVie About To Get A New Blockbuster Drug?
The Motley Fool -
AbbVie Inc. (NYSE:ABBV) Shares Acquired by Great Valley Advisor Group Inc.
Defense World -
AbbVie: Buy This Dividend King For A Growing Stream Of Income
Seeking Alpha -
Abbvie employees renovate North Chicago playground as part of company’s ‘Week of Possibilities’
Chicago Tribune -
AbbVie Inc. (NYSE:ABBV) Receives Consensus Rating of “Moderate Buy” from Brokerages
Defense World -
‘Thrilled to help’: AbbVie and Heart of America build STEM lab at Martin Elementary in Santa Ana
Los Angeles Times -
AbbVie Stock’s Healthy Yield Makes it a High-Conviction Holding
InvestorPlace 5 days ago -
AbbVie Rallies After Its Test of the Rising 200-Day Moving Average Line
TheStreet.com -
AbbVie (ABBV) Gains As Market Dips: What You Should Know
YAHOO!Finance -
AbbVie Foundation spruces up Forest Grove MS as part of annual Week of Possibilities
YAHOO!News
